Results 221 to 230 of about 8,203,949 (309)

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Basal forebrain and neural correlates of self-regulation traits in sustained attention. [PDF]

Imaging Neurosci (Camb)
Orsini C, Huber DA, Labek K, Bosch JE, Viviani R.   +4 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Assessment of the feed additive consisting of betaine anhydrous (3a920) for all animal species for the renewal of its authorisation (Genencor International B.V.). [PDF]

EFSA J
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Villa RE, Azimonti G, Bonos E, Christensen H, Durjava M, Dusemund B, Gehring R, Glandorf B, Kouba M, López-Alonso M, Marcon F, Nebbia C, Pechová A, Prieto-Maradona M, Theodoridou K, Anguita M, Galobart J, Innocenti ML, Manini P, Vettori MV, Pizzo F.   +21 more
europepmc   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

Molecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor, Julio Celis, Ulrik Ringborg   +2 more
wiley   +1 more source

The impact of university students' AI attitudes on AI-assisted creativity: the mediating role of AI usage motivation and the moderating role of AI dependency. [PDF]

Front Psychol
Yin J, Yuan T, Zhang Y, Yang G, Wang X.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Mentalization and Emotion Regulation in Adolescent Attachment: A Scoping Review. [PDF]

Children (Basel)
Salavou V, Papanikolaou K, Pehlivanidis A, Giannakopoulos G.   +3 more
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source